RxDoctor Payments Data

Claude Steriade, MD

Neurology · Cleveland, OHNPI 1013369446

Payments from drug & device makers

$391,620in general payments, 2019–2025

Across 96 payments — averaging $4079.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$197K
  • Genentech, Inc.$88K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
  • Neurelis, Inc.$20K
  • UCB, Inc.$11K
  • AbbVie$9K
  • plus $10K from 3 others

What the payments were for

  • Consulting fees$28,76655%
  • Speaking & faculty fees$21,88642%
  • Travel & lodging$4661%
  • Food & beverage$1,1372%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$391,620 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$46,382
Medicare patients
164
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FinteplaFenfluramine Hcl38$685,995
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$250,607
XcopriCenobamate125$243,309
EpidiolexCannabidiol (Cbd)48$201,744
AptiomEslicarbazepine Acetate21$98,948
OnfiClobazam31$86,592
VimpatLacosamide72$74,416
BriviactBrivaracetam37$73,686
Keppra XrLevetiracetam26$58,484
FycompaPerampanel32$41,238
FelbatolFelbamate25$37,489
ValtocoDiazepam27$35,808
LamictalLamotrigine40$34,912
ZonegranZonisamide14$29,839
Oxtellar XrOxcarbazepine17$26,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Vimpat, Briviact, Nayzilam$10,625$850,230163 claims
SK Life Science, Inc.Xcopri$4,001$243,309125 claims
Neurelis, Inc.Valtoco$20,152$35,80827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →